Premium
PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single‐drug pharmacogenetics
Author(s) -
Owen Ryan P.,
Altman Russ B.,
Klein Teri E.
Publication year - 2008
Publication title -
human mutation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 162
eISSN - 1098-1004
pISSN - 1059-7794
DOI - 10.1002/humu.20731
Subject(s) - pharmacogenetics , pharmacogenomics , biology , warfarin , bioinformatics , genetics , genotype , medicine , gene , cardiology , atrial fibrillation
PharmGKB, the pharmacogenetics and pharmacogenomics knowledge base ( www.pharmgkb.org ) is a publicly available online resource dedicated to the dissemination of how genetic variation leads to variation in drug responses. The goals of PharmGKB are to describe relationships between genes, drugs, and diseases, and to generate knowledge to catalyze pharmacogenetic and pharmacogenomic research. PharmGKB delivers knowledge in the form of curated literature annotations, drug pathway diagrams, and very important pharmacogene (VIP) summaries. Recently, PharmGKB has embraced a new role—broker of pharmacogenomic data for data sharing consortia. In particular, we have helped create the International Warfarin Pharmacogenetics Consortium (IWPC), which is devoted to pooling genotype and phenotype data relevant to the anticoagulant warfarin. PharmGKB has embraced the challenge of continuing to maintain its original mission while taking an active role in the formation of pharmacogenetic consortia. Hum Mutat 29(4), 456–460, 2008. © 2008 Wiley‐Liss, Inc.